SCML2

Across TCGA pan-cancer cohorts, SCML2 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of SCML2’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where SCML2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types SCML2 is over-expressed in tumor, although a few such as PDAC and LUAD show the opposite, repressed pattern.

LSCC, PDAC, and CCRCC are the cancer types where SCML2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SCML2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Male	All	+0.638	<.001	6	view →
PDAC	Female	All	−0.797	<.001	4	view →
CCRCC	Male	All	+0.469	.013	4	view →
LUAD	Female	All	−0.507	.003	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

SCML2–LSCC

Open the LSCC breakdown →